Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis

Authors: Lin Zhao, Shimiao Zhu, Ying Gao, Yaogang Wang

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

A HOXB13-to-IL17BR expression ratio was previously identified to predict a clinical outcome of breast cancer patients treated with adjuvant tamoxifen. A large number of studies were addressed to confirm its function as a predictor of breast cancer outcome treated with tamoxifen. However, conflicting results were got. In this study, a systematic search of databases was carried out, and other relevant papers were also identified. Then, the analyses were conducted according to the PRISMA and MOOSE guidelines. After full review, 11 studies with a total of 2,958 participants were deemed eligible and were included in the study. Pooled results revealed that women with higher HOXB13-to-IL17BR expression ratio had significantly worse outcomes in breast patients treated with tamoxifen, especially for those who are negative of node.
Literature
1.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
2.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRef
3.
Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–16.PubMedCrossRef
4.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–9.PubMedCrossRef
5.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9.PubMedCrossRef
6.
van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRef
7.
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, et al. A two-gene expression ratio of homeobox 13 and interleukin-17b receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006;12:2080–7.PubMedCrossRef
8.
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOBX13/IL17BR biomarker. J Natl Cancer Inst. 2013;105:1036–42.PubMedCentralPubMedCrossRef
9.
Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, et al. The HOBX13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24:4611–9.PubMedCrossRef
10.
Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009;113:275–83.PubMedCrossRef
11.
Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstrom P, Nordenskjold B, et al. Exploring the two-gene ratio in breast cancer-independent roles for HOBX13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008;107:225–34.PubMedCrossRef
12.
Habel LA, Sakoda LC, Achacoso N, Ma XJ, Erlander MG, Sgroi DC, et al. HOBX13: IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. Breast Cancer Res. 2013;15:R24.PubMedCentralPubMedCrossRef
13.
Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97:927–30.PubMedCrossRef
14.
Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van GM, van Staveren IL, et al. HOBX13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 2007;25:662–8.PubMedCrossRef
15.
Zhu S, Zhang H, Xie L, Chen J, Niu Y. Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis. J Urol. 2013;189:884–90.PubMedCrossRef
16.
Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2012;35:1388–93.PubMedCentralPubMedCrossRef
17.
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.PubMedCentralPubMedCrossRef
18.
Shang Z, Zhu S, Zhang H, Li L, Niu Y. Germline homeobox b13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24,213 cases and 73,631 controls. Eur Urol. 2013;64:173–6.PubMedCrossRef
19.
Okuda H, Toyota M, Ishida W, Furihata M, Tsuchiya M, Kamada M, et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene. 2006;25:1733–42.PubMedCrossRef
20.
Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, et al. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression. Cancer Res. 2013;73:5449–58.PubMedCentralPubMedCrossRef
Metadata
Title
Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis
Authors
Lin Zhao
Shimiao Zhu
Ying Gao
Yaogang Wang
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1403-x

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest

Research Article

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance

Research Article

d-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells

Research Article

Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C

Research Article

Absent expression of FLNA is correlated with poor prognosis of nasopharyngeal cancer

Research Article

Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits